Safety concerns for Gilead's Harvoni and Sovaldi were highlighted in the ISMP report, along with other direct-acting antivirals (DAAs) from AbbVie, Merck & Co, Bristol-Myers Squibb, and Johnson & Johnson, according to Fierce Pharma.